Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health Inc (NYSE: CAH) shares are trading lower after the company warned of additional inflationary effects and lower volumes from global supply chain constraints with lower-than-anticipated offset from pricing actions. As a result, the incremental impact will be nearly $150 million – $175 million on FY22 medical segment profit and $0.40 – $0.45 per share on non-GAAP EPS.

Cardinal Health Expects Inflationary Impact, Supply Chain Constraints To Hit Volumes In FY22

Cardinal Health CAH, +3.29% said Monday the impact of inflation and supply chain disruptions will reduce its fiscal 2022 medical segment unit profit by $150 million to $175 million. Cardinal Health now expects fiscal year 2022 profit that's 40 cents to 45 cents below its earlier expectations.

Cardinal Health lowers expectations for medical segment due to inflation, supply chain

DUBLIN, Ohio, Jan. 10, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today provided a fiscal year 2022 financial update for the Medical segment. The company now expects additional inflationary impacts and lower volumes resulting primarily from global supply chain constraints, and a lower-than-expected offset from pricing actions.

Cardinal Health Provides Medical Segment Fiscal Year 2022 Financial Update

DUBLIN, Ohio, Jan. 3, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2022 on February 3 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Webcast Discussion of Second-Quarter Results for Fiscal Year 2022 on February 3

Air Products and Chemicals

Bristol-Myers

Comcast

Cisco Systems

Illinois Tool Works

JPMorgan Chase & Co

Mastercard

Main Street Capital

Realty Income Corp

Stryker

Sysco

AT&T

Verizon

We provide a summary of upcoming ex-dividend dates in a quick reference table.

Upcoming Ex-Dividend Dates: December 30-January 7, 2022

AbbVie

Franklin Resources

Exxon Mobil

It is hard to believe 2021 is all but over and 2022 is upon us. The Santa Claus rally has carried the S&P 500 back to new all-time highs and everything seems set up for a strong January.

5 High-Yielding Dividend Aristocrats Are ‘Strong Buy' Stock Ideas for 2022

Manulife Financial

In 2022 high valuations will likely combine with the current Wall of Worry to create increased volatility (and more blue-chip investment opportunities for smart investors). Anti-bubble blue-chip investing is a great way to minimize risk, maximize safe yield, and can help you retire rich, and stay rich in retirement.

2 High-Yield Anti-Bubble Blue-Chip Bargains For A Rich 2022 And Beyond

Amcor Plc

Chevron

Con Ed

Emerson Electric

Leggett & Platt

Medtronic

People's United Financial

V.F.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger. The 65 Aristocrats screened as of December 23, 2021, represented all eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 14.59%-32.89% topped by MDT and LEG.

Top Dividend Aristocrats Tag 4 To Buy For January

AmerisourceBergen

Allstate

American Water Works

Baxter

Best Buy

Becton, Dickinson and Co.

Colgate-Palmolive

Discover

Enbridge

Gilead Sciences

Home Depot

Intel

Lockheed Martin

Masco

Packaging Corp of America

Philip Morris

T. Rowe Price Group

Texas Instruments

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

We explain why selling the cash-covered puts and covered calls is a safer choice and earns a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.

Options Income Series: Earn High Income Safely And Consistently - December 2021

Costco

GlaxoSmithKline

Pfizer

Smith & Wesson Brands

Watching the developments of the Covid-19 crisis, it could become endemic. Here's what that means for certain stocks to buy.

7 Stocks to Buy if Covid-19 Becomes Endemic

Broadcom

Bank of Nova Scotia

CME Group

McCormick

Altria

Nucor

SPDR S&P 500 ETF Trust

W. P. Carey

Xcel Energy

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: December 21-January 3, 2021

MDU Resources Group

Novartis

Northwest Natural Gas

This holiday season, there are many reasons for investors to be joyful and nervous. Very high market valuations could result in years of disappointing returns after a decade of Buffett-like annual returns.

Santa Is Delivering 10 High-Yield Dividend Aristocrat Bargains You Won't Want To Miss

Cardinal Health has a strong track record of revenue growth, which continued in the latest quarter. Management expects supply chain disruptions to subside by the end of the current fiscal year.

Cardinal Health Is A Great Bargain Buy, Here's Why

Not only do these companies they offer high-yielding payouts, but they have solid track records of boosting them regularly.

Want to Collect $500 Each Month? Invest $123,553 Into These 3 Dividend Stocks

British American Tobacco

Imperial Brands PLC

Red Electrica Corp SA

Sanofi

Swiss Re AG

Unilever

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

15 Best Dividends On Earth Priced To Buy In December

News for Cardinal Health Stock (CAH)